Prostate cancer is often an indolent disease, and delays in treatment up to 6 months do not seem to affect cancer-free survival. Inadequate pre-treatment assessment and uninformed shared decision-making can lead to decision regret and disparities in receipt of treatments. Time is on our side to allocate sufficient time and resources to consider the most appropriate and individualized treatment decision in prostate cancer care.
- Nynikka R. Palmer
- Peter R. Carroll
- Samuel L. Washington III
